Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ATG-101 |
Synonyms | |
Therapy Description |
ATG-101 is a tetravalent bispecific antibody targeting PD-L1 (CD274) and TNFRSF9 (4-1BB), which activates TNFRSF9 (4-1BB) signaling and blocks PD-1/PD-L1 interaction, potentially leading to an enhanced antitumor immune response and inhibition of tumor growth (PMID: 38501978). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATG-101 | ATG101|ATG 101|xirestomig | Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 119 TNFRSF9 Antibody 31 | ATG-101 is a tetravalent bispecific antibody targeting PD-L1 (CD274) and TNFRSF9 (4-1BB), which activates TNFRSF9 (4-1BB) signaling and blocks PD-1/PD-L1 interaction, potentially leading to an enhanced antitumor immune response and inhibition of tumor growth (PMID: 38501978). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04986865 | Phase I | ATG-101 | A Study of Evaluating the Safety and Efficacy of ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas (PROBE) | Recruiting | USA | AUS | 0 |